Clinical trials: Chronic Hepatitis B Infections
Chronic Hepatitis B
Study of GST-HG131&141 Tablets Compared With Placebo in Patients With Chronic Hepatitis B
A randomized, double-blind, placebo-controlled Phase IIa clinical study to evaluate the safety and efficacy of GST-HG131/GST-HG141 tablets in patients with chronic hepatitis B
- Trial name
- NCT07709520
- Testing
- GST-HG141, GST-HG131
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Fujian Akeylink Biotechnology Co., Ltd.
Chronic Hepatitis b
Evaluate the Safety and Efficacy of STSG-0002 Injection in Patients With Chronic Hepatitis B
This trial is a multi-center, open, single-dose, dose-increasing trial，to evaluate the safety and efficacy of STSG-0002 injection in patients with chronic hepatitis B treated with oral antiviral therapy(Long-term follow-up).
- Trial name
- NCT05760703
- Testing
- STSG-0002 Injection
- Where
- 4 sites in China
- Volunteers
- 9 people
- Sponsor
- Staidson (Beijing) Biopharmaceuticals Co., Ltd
Chronic Hepatitis B
A Study to Evaluate Addition of Peginterferon Alfa-2a to Chronic Hepatitis B (CHB) Patients Treated With NAs
This study evaluates whether addition of Peginterferon alfa-2a to CHB Patients Treated with nucleoside analogues (NAs) can enhance the rate of HBsAg clearance at end of treatment.
- Trial name
- NCT02894918
- Testing
- Peginterferon alfa-2a
- Where
- 5 sites in China
- Volunteers
- 114 people
- Sponsor
- Henan Provincial People's Hospital
Hepatitis B
Safety and Efficacy Study of L-FMAU in Chronic HBV Patients of L-FMAU-201 Placebo Group
The purpose of this study is to evaluate the safety and antiviral activity of clevudine 30 mg QD for treatment of longer period (24 weeks) in patients chronically infected with HBV.
- Trial name
- NCT00313261
- Testing
- Clevudine
- Where
- 7 sites in South Korea
- Sponsor
- Bukwang Pharmaceutical
Chronic Hepatitis b
Study on Effect of Intestinal Microbiota Transplantation in Chronic Hepatitis B
Chronic hepatitis B(CHB) is a common infectious disease affecting up to 2 billion people worldwide. Around 650 thousand people died of liver failure, cirrhosis and primary liver cancer caused by chronic hepatitis B every year.
- Trial name
- CHB (NCT03429439)
- Testing
- intestinal microbiota transplant, Antiviral Agents
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Zhongshan Hospital Xiamen University
Chronic Hepatitis B
A Phase 1 Study of GC1102 (Recombinant Hepatitis B Immunoglobulin) in Chronic Hepatitis B Patients
This study is SAD(Single Ascending Dose)/MAD(Multiple Ascending Dose) study to Explore the Tolerability, Safety and Pharmacokinetics/Pharmacodynamics of GC1102 (Recombinant Hepatitis B Human Immunoglobulin) in Chronic Hepatitis B…
- Trial name
- NCT02569372
- Testing
- GC1102
- Where
- South Korea
- Volunteers
- 53 people
- Sponsor
- Green Cross Corporation
Chronic Hepatitis, Liver Cirrhosis
Hepatocyte-specific Versus Extracellular Contrast Agents for Liver MRI: Prospective, Intra-individual Comparison of Diagnostic Performance for Hepatocellular Carcinoma
Adult patients with chronic hepatitis B and cirrhosis of any etiology who are found to have suspected liver cancer are potentially eligible for the study.
- Trial name
- NCT03892681
- Testing
- hepatocyte-specific contrast agent, extracellular contrast agent
- Where
- South Korea
- Volunteers
- 129 people
- Sponsor
- Yonsei University
Liver Cirrhosis, Chronic Hepatitis B
Study on the Pharmacokinetic Characteristics of I.V. Hepabig Injection Used for Prevention of Hepatitis B Relapse After Liver Transplantation
An exploratory clinical trial to evaluate the pharmacokinetic characteristics of I.V. Hepabig injection used for prevention of hepatitis B relapse after liver transplantation.
- Trial name
- LT (NCT02125071)
- Testing
- Blood Sample Collection
- Where
- South Korea
- Volunteers
- 20 people
- Sponsor
- Dong-Gu Kim
Hepatitis; Virus, Chronic, Type B
A Clinical Trials to Evaluate the Efficacy and Safety of Tenofovir With and Without DWPUR001 in Patients With HBV
The patient who meets the inclusion/exclusion criteria is assigned to Test1 group or Test 2 group or control group randomly. All subjects take one pill of Viread® Tab.
- Trial name
- NCT02966964
- Testing
- DWPUR001
- Where
- 6 sites in South Korea
- Volunteers
- 90 people
- Sponsor
- Uijeongbu St. Mary Hospital
Hepatitis C Virus Infection
Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination in Adults With Chronic HCV and HBV Coinfection
The primary objectives of this study are to determine the antiviral efficacy, safety, and tolerability of ledipasvir/sofosbuvir (LDV/SOF) fixed-dose combination (FDC) in adults with chronic genotype 1 or 2 HCV infection who are…
- Trial name
- NCT02613871
- Testing
- LDV/SOF
- Where
- 8 sites in Taiwan
- Volunteers
- 111 people
- Sponsor
- Gilead Sciences
Chronic Hepatitis B
PEG-IFN in HBV Patients With Incomplete Response to NA
Treatment with a nucleoside analogue and subsequent viral decline has shown to partially restore immune hyporesponsiveness in chronic hepatitis B patients.
- Trial name
- PADD (NCT00883844)
- Testing
- Nucleos(t)ide analogue treatment with a peginterferon add-on strategy, Nucleos(t)ide analogue treatment
- Where
- 2 sites in Netherlands
- Volunteers
- 11 people
- Sponsor
- Foundation for Liver Research
Hepatitis B
First-In-Human Study of ChAdOx1-HBV & MVA-HBV Vaccines (VTP-300) for Chronic HBV
This is an open-label study to determine the safety, tolerability and immunogenicity of ChAdOx1-HBV and MVA-HBV vaccines, with or without nivolumab, in patients with chronic HBV who are virally suppressed with oral anti-viral…
- Trial name
- NCT04778904
- Testing
- ChAdOx1-HBV, MVA-HBV, Nivolumab
- Where
- 12 sites in South Korea, Taiwan and 1 more
- Volunteers
- 55 people
- Sponsor
- Barinthus Biotherapeutics
Hepatitis B, Chronic
A Study of PEGASYS (Peginterferon Alfa-2a [40KD]) in Patients With Hepatitis B e Antigen (HBeAg)-Negative Chronic Hepatitis B Virus (HBV)
This study will evaluate the efficacy, safety, and tolerability of PEGASYS in participants with HBeAg-negative chronic HBV. The anticipated time on study treatment is 48 weeks, and the target sample size is 60 individuals.
- Trial name
- NCT02570191
- Testing
- Peginterferon alfa-2a
- Where
- 8 sites in Bulgaria
- Volunteers
- 60 people
- Sponsor
- Hoffmann-La Roche
Hepatitis B,Chronic, Carcinoma,Hepatocellular
The Development of Diagnostic Biomarker Panels for Hepatitis and Liver Cancer
More recent studies have shown that the HBV-infected population has a greater risk of development of hepatocellular carcinoma. Nevertheless, there are still a significant number of people chronically infected by HBV who do not…
- Trial name
- NCT01310062
- Where
- 8 sites in Malaysia
- Volunteers
- 1,600 people, healthy volunteers welcome
- Sponsor
- Ministry of Health, Malaysia
Hepatitis B, Chronic
A Study of Treatment With RO6864018 in Virologically Suppressed Participants With Chronic Hepatitis B Virus (HBV) Infection
This randomized, multicenter, partially double-blind, placebo-controlled study is designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and antiviral effects of treatment with RO6864018 in…
- Trial name
- NCT02391805
- Testing
- Entecavir, RO6864018, Tenofovir
- Where
- 14 sites in Hong Kong, Malaysia and 4 more
- Volunteers
- 31 people
- Sponsor
- Hoffmann-La Roche
Hepatitis B
Efficacy and Safety of Telbivudine in Treatment naïve Patients With Hepatitis B e Antigen (HBeAg)-Positive Chronic Hepatitis B (CHB)
To evaluate the combination of telbivudine 600 mg orally (PO) once daily and peginterferon alpha-2a 180 ug subcutaneous (sq) injection weekly for antiviral efficacy in comparison to peginterferon alpha-2a monotherapy.
- Trial name
- NCT00412750
- Testing
- Telbivudine (LdT), peginterferon alpha-2a
- Where
- United States
- Volunteers
- 159 people
- Sponsor
- Novartis
Chronic Hepatitis B
A Study to Evaluate AHB-137 Injection in Treatment-naïve Participants With Chronic Hepatitis B
This study is a randomized, double-blind, placebo-controlled, multicenter phase 2 study to assess the efficacy and safety of AHB-137 injection in treatment-naïve participants with chronic hepatitis B.
- Trial name
- NCT07635186
- Testing
- AHB-137
- Where
- 34 sites in China
- Volunteers
- 320 people
- Sponsor
- Ausper Biopharma Co., Ltd.
Chronic Hepatitis B
Composite Probiotics Stabilize Lipid Metabolism in Chronic Hepatitis B Patients:A Clinical Trial
The goal of this is to verify the clinical efficacy of compound probiotics in reducing HBV infection levels and regulating intestinal flora in patients with chronic hepatitis B.
- Trial name
- NCT06221605
- Testing
- Probiotic
- Where
- China
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- Wecare Probiotics Co., Ltd.
HBe Negative Chronic Hepatitis B, Hepatitis B Viral Infection
ANRS HB 05 Multicenter Study Evaluating Efficacy and Safety of Clevudine Monotherapy Versus Tenofovir Monotherapy Versus Combination Therapy of Clevudine and Tenofovir for 96 Weeks in HBeAg Negative Patients With Chronic Hepatitis B, naïve to Anti-VHB Therapy
For chronic HBV infection, an optimal pharmacological agent to promote recovery from chronic HBV infection would be one that inhibits HBV DNA polymerase, combined with the clearence from the liver of cccDNA to block HBV…
- Trial name
- NCT00823342
- Testing
- CLEVUDINE IN ASSOCIATION TENOFOVIR
- Where
- France
- Volunteers
- 150 people
- Sponsor
- French National Agency for Research on AIDS and Viral Hepatitis
Hepatitis B, Chronic
Compare Continuing Lamivudine Plus Adefovir or Adefovir Versus Switching to Entecavir Plus Adefovir in Patients With LAM-resistant Chronic Hepatitis B
The purpose of this study is to compare efficacy and safety of continuing Lamivudine plus Adefovir or Adefovir versus switching to Entecavir plus Adefovir in patients with LAM-resistant chronic hepatitis B who have suboptimal…
- Trial name
- NCT02482272
- Testing
- Lamivudine, Adefovir, Entecavir
- Where
- South Korea
- Volunteers
- 90 people
- Sponsor
- Asan Medical Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.